1-12 of 12
Hui Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Open Access
Lillian K. Skidmore, David Mills, Ji Young Kim, Nick A. Knudsen, Jay D. Nelson, Manoj Pal, Jianing Wang, Kedar GC, Michael J. Gray, Wisam Barkho, Prathap Nagaraja Shastri, Mysore P. Ramprasad, Feng Tian, Daniel O’Connor, Ying J. Buechler, Shawn Shao-Hui Zhang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (12): 1842–1853.
https://doi.org/10.1158/1535-7163.MCT-23-0927
Published: 03 December 2024
View articletitled, Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C160: HMPL-653, a highly potent and selective CSF-1R inhibitor, targeting both tumor cells and tumor microenvironment

Free
Jia Hu, Liang Ge, Hui Zhang, An Jiang, Juntao Yu, Weifang Xue, Jian Wang, Yang Sai, Na Yang, Weiguo Qing, Yongxin Ren, Michael Shi, Weiguo Su
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C160.
https://doi.org/10.1158/1535-7163.TARG-23-C160
Published: 01 December 2023
View articletitled, Abstract C160: HMPL-653, a highly potent and selective CSF-1R inhibitor, targeting both tumor cells and tumor microenvironment
Journal Articles

Abstract A094: Preclinical characterization of HMPL-415, a second-generation SHP2 inhibitor

Free
Jia Hu, Jun Ni, Zhihu Gao, Xiaoqing Liu, Hui Zhang, Pan Wang, Min Cheng, Guanglin Wang, Zeyu Zhong, Jian Wang, Yang Sai, Na Yang, Weiguo Qing, Yongxin Ren, Michael Shi, Weiguo Su
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A094.
https://doi.org/10.1158/1535-7163.TARG-23-A094
Published: 01 December 2023
View articletitled, Abstract A094: Preclinical characterization of HMPL-415, a second-generation SHP2 inhibitor
Journal Articles

Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas

Available to Purchase
Hui Zhang, Yongyan Bi, Yuxi Wei, Jiayang Liu, Kudelaidi Kuerban, Li Ye
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (7): 1305–1315.
https://doi.org/10.1158/1535-7163.MCT-20-0825
Published: 01 July 2021
View articletitled, Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas
Open the PDF for Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas in another window
Includes: Supplementary data
Journal Articles

Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma

Free
Carrie J. Li, Changying Jiang, Yang Liu, Taylor Bell, Wencai Ma, Yin Ye, Shengjian Huang, Hui Guo, Hui Zhang, Lai Wang, Jing Wang, Krystle Nomie, Liang Zhang, Michael Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (2): 267–277.
https://doi.org/10.1158/1535-7163.MCT-18-0478
Published: 04 February 2019
View articletitled, Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma
Open the PDF for Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract A114: SIRT2 directs DNA-PKcs in the DNA damage response

Free
Pamelasara E. Head, Hui Zhang, David S. Yu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A114.
https://doi.org/10.1158/1535-7163.TARG-17-A114
Published: 01 January 2018
View articletitled, Abstract A114: SIRT2 directs DNA-PKcs in the DNA damage response
Journal Articles

The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors

Free
Hui Zhang, Atish Patel, Yi-Jun Wang, Yun-Kai Zhang, Rishil J. Kathawala, Long-Hui Qiu, Bhargav A. Patel, Li-Hua Huang, Suneet Shukla, Dong-Hua Yang, Suresh V. Ambudkar, Li-Wu Fu, Zhe-Sheng Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (6): 1021–1030.
https://doi.org/10.1158/1535-7163.MCT-16-0511
Published: 01 June 2017
View articletitled, The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors
Open the PDF for The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors in another window
Includes: Supplementary data
Journal Articles

CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation

Free
Dan-Dan Wang, Ying Chen, Zi-Bo Chen, Fang-Jie Yan, Xiao-Yang Dai, Mei-Dan Ying, Ji Cao, Jian Ma, Pei-Hua Luo, Yong-Xin Han, Yong Peng, Ying-Hui Sun, Hui Zhang, Qiao-Jun He, Bo Yang, Hong Zhu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (12): 2916–2925.
https://doi.org/10.1158/1535-7163.MCT-16-0282
Published: 01 December 2016
View articletitled, CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation
Open the PDF for CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation in another window
Includes: Supplementary data
Journal Articles

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer

Free
Ming-Wu Zheng, Chun-Hui Zhang, Kai Chen, Mei Huang, Ya-Ping Li, Wan-Ting Lin, Rong-Jie Zhang, Lei Zhong, Rong Xiang, Lin-Li Li, Xin-Yu Liu, Yu-Quan Wei, Sheng-Yong Yang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (3): 366–378.
https://doi.org/10.1158/1535-7163.MCT-15-0501
Published: 06 March 2016
View articletitled, Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer
Open the PDF for Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C98: Quizartinib (AC220) potentiates the antineoplastic activity of wild-type ABCG2 and ABCB1 substrates.

Free
Priyank Kumar, Rishil J. Kathawala, Hui Zhang, Nagaraju Anreddy, Yanglu Chen, Kanav Gupta, Louis D. Trombetta, Zhe S. Cheng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C98.
https://doi.org/10.1158/1535-7163.TARG-13-C98
Published: 01 November 2013
View articletitled, Abstract C98: Quizartinib (AC220) potentiates the antineoplastic activity of wild-type ABCG2 and ABCB1 substrates.
Journal Articles

Abstract C130: Inhibition of NF-κB activity promotes radiosensitivity of breast cancer cells in three-dimensional culture via a β1-integrin-mediated pathway.

Free
Kazi M. Ahmed, Hui Zhang, Catherine C. Park
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C130.
https://doi.org/10.1158/1535-7163.TARG-11-C130
Published: 12 November 2011
View articletitled, Abstract C130: Inhibition of NF-κB activity promotes radiosensitivity of breast cancer cells in three-dimensional culture via a β1-integrin-mediated pathway.
Journal Articles

Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice

Free
Tao Bian, Yue Wang, Zhenhua Lu, Zhenmei Ye, Li Zhao, Jiao Ren, Hui Zhang, Li Ruan, Houwen Tian
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (5): 1329–1335.
https://doi.org/10.1158/1535-7163.MCT-07-2015
Published: 15 May 2008
View articletitled, Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice
Open the PDF for Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice in another window